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Infliximab treatment for steroid-refractory acute
graft-versus-host disease
Transplantation with allogeneic marrowor peripheral blood hematopoietic stemcells (HSCT) has been increasingly per-
formed for a wide variety of hematologic
diseases in the last two decades. Acute
graft-versus-host disease (GVHD) is a com-
mon cause of significant morbidity and mor-
tality after allogeneic HSCT, especially in
patients in whom first-line treatment with
high-dose steroids has failed. Insights into
the pathophysiology of GVHD have indicat-
ed that the gastrointestinal tract is not only
a major target organ of GVHD, but also that
it has a critical role in initiating and ampli-
fying the inflammatory process.1 Both
inflammatory cytokines and cells from the
donor and the host contribute to the tissue
damage of GVHD. Tumor necrosis factor α
(TNF-α) emerged as a key cytokine in the
inflammatory cascade of acute GVHD. In
fact, this cytokine, secreted together with
interleukin-1 by the macrophages of the
host gastrointestinal tract damaged by drugs
of the conditioning regimen, leads to donor
T- cell proliferation and secretion of inter-
leukin-2 and interferon-α, with further
amplification of T-lymphocytes and mono-
nuclear phagocyte responses. Damage to the
intestinal mucosa allows translocation of
lipopolysaccharides of the normal bowel flo-
ra and other immuno-stimulatory molecules
from the intestinal lumen to the circulation,
propagating the cytokine storm characteris-
tic of acute GVHD. 
Serum levels of TNF-α and soluble TNF-α
receptors I and II increase in patients with
acute GVHD and have been shown to be
sensitive and specific parameters for this
complication.2-4 Some clinical experience has
suggested that infliximab, an antibody
against TNF-α, can have beneficial effects in
patients with steroid-refractory acute
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Background and Objectives. Tumor necrosis factor α is one of the principal cytokines
involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an
antibody to this cytokine.  
Design and Methods. We performed a retrospective analysis to evaluate the activity of
infliximab in 32 patients with severe steroid-refractory acute GVHD. The patients received
a median of 3 weekly courses of infliximab. The main organs involved in the patients were
skin (n=2) liver (n=1), bowel (n=19), liver and bowel at the same stage (n=10).
Results. Nineteen out 32 patients (59%) responded to infliximab with 6 (19%) com-
plete and 13 (40%) partial responses. Age younger than 35 years, intestinal involvement
and a longer time between hematopoietic stem cell transplantation and infliximab admin-
istration were factors predicting a favorable response. Infective episodes developed in
23/32 (72%) patients. All the 13 unresponsive patients died of GVHD shortly after inflix-
imab. Thirteen of 19 responsive patients were alive at a median follow-up of 449 days
(range 155-842) after infliximab, with no signs of chronic GVHD (n=5), limited (n=5) or
extensive involvement (n=3). Six patients who responded subsequently died, one of chron-
ic lung GVHD, the others of vascular complications or infections (2 fungal diseases).
Interpretation and Conclusions. We conclude that infliximab is active in the treatment
of severe steroid-refractory acute GVHD, particularly when the intestine is involved. Infec-
tions commonly followed its administration. The clinical activity of infliximab and the pos-
sibility that it increases the risk of infections are worth investigating in prospective tri-
als. 
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GVHD.5-12 Infliximab, already approved for clinical use
in rheumatoid arthritis and Crohn’s disease, is a
chimeric mouse/human IgG1κ antibody that binds with
high affinity to soluble and transmembrane forms of
human TNF-α. Binding to soluble TNF-α results in the
neutralization of its activity, whereas binding to the
transmembrane form of TNF-α causes lysis of the
affected cells by activation of complement and induc-
tion of antibody-mediated cellular toxicity.13 In a mouse
model, blocking LIGHT (a T-cell co-stimulatory molecule
belonging to the TNF-α superfamily), with monoclonal
antibodies led to a persistent anergy of CD4 T lympho-
cytes and prevented acute GVHD after infusion of
immuno-competent allogeneic donor cells.14
Based on these findings, we conducted a retrospec-
tive analysis to evaluate the activity of infliximab in
steroid-refractory acute GVHD. 
Design and Methods 
Patients 
Thirty-two patients receiving an allogeneic HSCT for
a neoplastic disease between June 2000 and December
2004 were retrospectively analyzed. Clinical and labo-
ratory data of the patients were collected through a
questionnaire sent to 26 major Italian Transplant Units
for children and adult patients. Eight Hematology Cen-
ters replied that they had some experience with inflix-
imab treatment and sent the data on 32 patients. All
subjects met the following eligibility criteria: (i) diag-
nosis of hematologic or solid tumor; (ii) non-T-cell-
depleted transplant from an HLA-matched sibling or
unrelated donor (fully matched for HLA-A,-B, -DR by
serological and molecular testing); (iii) development of
acute GVHD ≥ grade II refractory to prednisone thera-
py; (iv) salvage treatment with infliximab (RemicadeTM).
The patients’ characteristics are shown in Table 1. The
median age at transplant was 39 years (range 2-66).
Seven patients were younger than 14 years. Twenty-
two of the 32 patients were male (69%). The hemato-
logic diseases necessitating transplantation were acute
leukemia (n=14), chronic myeloid leukemia (n=6), lym-
phoma (n=4), multiple myeloma (n=5) Fanconi’s anemia
(n=1) renal carcinoma (n=1), and prostatic carcinoma
(n=1). The median time between diagnosis and trans-
plant was 16 months (range 4-68). Nine out the 32
patients (28%) were transplanted in a late phase of dis-
ease after heavy pre-treatment (previous autologous
stem cell transplantation and/or ≥ 3 chemotherapy reg-
imens). All the patients provided written informed con-
sent to the allogeneic HSCT and infliximab administra-
tion under studies approved by the local Ethical Com-
mittees. 
Transplant-related data
Stem cells were harvested from sibling donors for 18
patients (56%) and from unrelated donors for the oth-
er 14 patients (44%). Thirteen patients (41%) received
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Table 1. Clinical characteristics of the patients treated
with infliximab.
Clinical characteristics No. of patients (%)
Age at HSCT (years)





Acute myeloid leukemia 9 28
Acute lymphocytic leukemia 5 16
Chronic myeloid leukemia 6 18
Lymphoma 4 13
Myeloma 5 16
Solid tumor 2 6
Fanconi’s anemia 1 3
Heavy pretreatment 9 28
Time diagnosis-HSCT






BU±CY± melphalan 10 31
Reduced intensity 13 41











Liver + bowel 10 31%
GVHD treatment prior to infliximab 
Cyclosporine A 26 81%
Prednisone 32 100%
ATG 12 38%
Other drugs 11 34%
(HSCT: hematopoietic stem cell transplantation; TBI: total body irradiation;
BU: busulfan; CY: cyclophosphamide; BM : bone marrow;
PB: peripheral blood; GVHD: graft-versus-host disease;
ATG: anti-human T lymphocyte serum).
 
marrow cells and 19 (59%) peripheral blood stem cells.
The conditioning regimen used conventional myeloab-
lative doses for 19 patients (59%), who received total
body irradiation and cyclophosphamide (n=9) or busul-
fan plus cyclophosphamide or melphalan (n=10) and
was of reduced intensity for 13 patients (41%), who
were treated with fludarabine, thiotepa, cyclophos-
phamide (n=10), fludarabine plus cyclophosphamide
(n=1), fludarabine, thiotepa, melphalan (n=1), or 2 Gy
total body irradiation (n=1). 
Antibiotic prophylaxis with levofloxacin was admin-
istered after HSCT until complete neutrophil recovery.
An antifungal drug, fluconazole or itraconazole, was
used until all immunosuppressive drugs were with-
drawn. In addition, trimethoprim-sulphamethoxazole
was used to prevent Pneumocystis carinii pneumonia.
Cytomegalovirus (CMV) infection was monitored week-
ly by CMV antigenemia. If CMV antigenemia tests
became positive, patients were treated with ganciclovir
or foscarnet.
GVHD prophylaxis included cyclosporine A (CyA) and
methotrexate for 24 patients (75%), CyA alone for 5
patients (16%), tacrolimus for 1 patients (3%) and CyA
plus mycophenolate mofetil (MMF) for the other 2
patients (6%). Anti-human T lymphocyte rabbit serum
(ATG) was administered in association with CyA and
methotrexate in 12 patients (37%) receiving unrelated
transplants.
The assessment and grading of acute and chronic
GVHD were primarily based on clinical findings and fol-
lowed the commonly accepted diagnostic criteria.15,16
Diagnosis was supported by skin, liver or gut biopsies,
whenever indicated and clinically possible. Patients with
diarrhea who could not undergo colonoscopy had stool
cultures negative for bacteria, fungi and protozoa. 
Response was assessed for each organ involved 7 days
after the initiation of infliximab. A complete response
was defined as resolution of all manifestations of acute
GVHD in all evaluable organs, a partial response was
defined as a decrease in organ stage by 1 in at least one
evaluable organ without deterioration of others. Unre-
sponsive patients had an increase of 1 in organ stage
in at least one evaluable organ or absence of any
change after infliximab.
All patients developing grade II-IV acute GVHD
received 2-5 mg/kg/day methylprednisolone i.v. for 7
days; if no partial or complete resolution of symptoms
occurred, they were considered steroid-refractory and
proceeded to infliximab treatment. The dose of inflix-
imab was 10 mg/kg/day i.v. weekly and at least 2 cours-
es were given. 
Statistical analysis
Patients responsive and unresponsive to infliximab
treatment were compared on the basis of several of
their clinical characteristics and features of the graft.
Categorical variables were compared using χ2 statistics
or Fisher’s exact test and continuous values were com-
pared with the two-sided Student’s test. A p value
<0.05 was considered to be statistically significant.
Survival was estimated by the Kaplan-Meier product
limit method and curves from different groups were
compared by the log-rank test. 
Results
The median time between the allogeneic HSCT and
diagnosis of acute GVHD was 22 days (range 9-161). All
but 2 cases were taking some form of prophylaxis (27
Cy, 1 prednisone, 2 tacrolimus) at the moment of GVHD
onset. The 2 patients who were not receiving any pro-
phylaxis were being given donor leukocyte infusions for
disease relapse. All the patients showed clinical fea-
tures of acute GVHD: the main organs involved were the
skin in 2 cases (6%), liver in 1 case (3%), bowel in 19
cases (60%), liver and bowel at the same stage in 10
patients (31%). The diagnosis of GVHD was confirmed
by 7 intestinal, 2 cutaneous and 1 hepatic biopsies.
GVHD was overall classified as grade 2 in 4 patients
(12%), grade 3 in 8 patients (25%) and grade 4 in 20
patients (63%).
First-line therapy for the acute GVHD was 2-5
mg/kg/day methylprednisone i.v. in all patients, in asso-
ciation with CyA (n=26) or tacrolimus (n=1) or MMF
(n=5). All the patients were steroid-refractory, since
they had no improvement after at least 7 days of treat-
ment. Twelve patients were subsequently treated with
ATG, 2 with methotrexate, 3 with photophoresis and 1
with cyclophosphamide without any improvement,
before receiving infliximab. Overall, infliximab courses
were administered to 14 patients (44%) as second-line
therapy, after failure of prednisone and CyA (or
tacrolimus or MMF) and as third-line therapy to anoth-
er 18 patients (56%) who did not respond to second-
line therapy.
The median time between HSCT and infliximab
administration was 47 days (range 19-262); 27 of the
32 patients (84%) were treated within 30 days after
the onset of GVHD, the remaining 5 patients received
infliximab after 70, 129, 134, 220 and 240 days. Inflix-
imab was administered at the dose of 10 mg/kg/day i.v.
weekly for a median of 3 courses (range 2-8) without
infusion-related side-effects. Steroid doses were main-
tained between 1-2 mg/kg/day for all patients during
the therapy with infliximab. Nineteen of the 32 patients
(59%) responded to infliximab: responses were com-
plete in 6 patients (19%) and partial in 13 patients
(40%). Fifteen out of the 19 responsive patients had
predominant intestinal involvement, whereas 4 had liv-
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er involvement with significantly increased bilirubin
levels, associated with skin or bowel disease. The medi-
an level of serum birilubin of these cases was 5.5 mg/dL
before infliximab and 1.7 mg/dL after treatment.  After
infliximab, Cy A and prednisone were gradually tapered
down and then definitively stopped in 6 and 4 respon-
sive patients, respectively. No patient who responded
received ATG whereas 8 patients received other immu-
nosuppressive therapies, such as tacrolimus (n=3), MMF
(n=2), cyclophosphamide (n=1), or photophoresis (n=1)
(Figure 1A). In the group of unresponsive patients,
steroids were not suspended in any patients: 4 received
ATG and 8 received other treatments, which were
tacrolimus (n=2), MMF (n=2), methotrexate (n=2),
cyclophosphamide (n=2) (Figure 1B).
Twenty-two out 32 patients (72%) developed one or
more infectious episodes after infliximab: there were 7
cases of septicemias (5 Gram-positive and 2 Gram-neg-
ative), 2 cases of septic shock, 2 cases of pneumonia of
bacterial origin and 5 caused by an undetermined eti-
ologic agent, 4 cases of infectious enteritis, 1 case of
encephalitis, 13 cases of CMV reactivation (document-
ed by positive antigenemia) and 2 proven invasive
mycotic infections (candidemia and pulmonary
Figure 1. Modification of immunosuppressive therapy in patients responsive (1A) and unresponsive (1B) to infliximab
treatment. (CyA: cyclosporine A; PDN: prednisone; ATG: anti-human T lymphocyte serum; other: tacrolimus, mycophe-
nolate mofetil, cyclophosphamide, methotrexate or photophoresis).  
CyA PDN ATG other
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aspergillosis). All the 13 unresponsive patients died of
GVHD at a median time of 43 days (range 14-450) after
its onset. Thirteen of the 19 responsive patients (68%)
were still alive at a median follow-up of 630 days
(range 300-1170) after HSCT and 449 days (range 155-
842) after the infliximab treatment. Five out of the 19
(26%) responsive patients had no signs of chronic
GVHD, 5 (26%) had limited and 3 (16%) had extensive
chronic GVHD. Six out the 19 (32%) responsive patients
died: 3 because of infections ( mycotic pneumonia, can-
didemia, encephalitis), 1 of thrombotic thrombocy-
topenic purpura, 1 of ischemic stroke with concomitant
evidence of sepsis and 1 of respiratory failure due to
lung GVHD. Four patients (12%) had evidence of disease
relapse or progression after HSCT (3 lymphomas and
one chronic myeloid leukemia transplanted in blastic
phase). Survival curves after infliximab are shown in
Figure 2.  Patients who did or did not respond to inflix-
imab were compared on the basis of several clinical
features (sex, age, disease diagnosis, phase of disease,
previous treatment), characteristics of their transplan-
tation (myeloablative or reduced-intensity treatment,
source of stem cells, type of donor) and GVHD features
(time between HSCT and GVHD onset or first dose of
infliximab, main organ involvement, infliximab as sec-
ond or third-line treatment for GVHD), The analysis
showed that age under 35 years, a predominant intes-
tinal involvement (with no liver GVHD) and a longer
time between HSCT and infliximab administration were
associated with a favorable response to infliximab, as
shown in Table 2. Patients with concomitant hepatic
and intestinal GVHD had a significant adverse outcome
after infliximab treatment.
Discussion
We conducted a multicenter retrospective study of 32
patients with steroid-refractory grade II-IV acute GVHD.
More than half of them had grade IV GVHD and all but
3 had gastrointestinal involvement. Patients had a uni-
form conventional first-line treatment with high-dose
prednisone and were evaluated as unresponsive after a
7-day course. Infliximab was added as a second-line
drug in 14 patients whereas it was used as third-line
salvage treatment in 18 patients. We report an encour-
aging response rate: 19% complete and 40% partial
responses according to standard clinical criteria. It is
worth noting that the amount of GVHD therapy could
be reduced in patients responding to infliximab, where-
as no drugs could be tapered down or withdrawn in the
unresponsive patients and sometimes new therapies,
such as ATG, had to be added.
That infliximab was clinically effective in acute GVHD
had been suggested by a few case-reports and small
series reported in the literature. Kobbe et al.5 described
that 3 of 4 patients with acute stage III or IV intestin-
al GVHD refractory to high-dose steroids improved after
infliximab administration. The MD Anderson group6,8
reported the largest experience in acute (37 patients)
and chronic GVHD (26 patients), with an overall
response rate of 70% and the greatest benefit in cases
with lower gastrointestinal tract involvement. Recent-
ly, Couriel et al.12 confirmed these data in 21 patients in
whom infliximab was added as a single agent to
tacrolimus and corticosteroids for the initial treatment
of steroid-resistant acute GVHD: complete responses
were obtained in 62% with the best responses occur-
ring in patients with gastrointestinal and cutaneous
GVHD. Other groups7,9-11,18 observed some responses in
series between 5 and 11 cases with acute or chronic
GVHD unresponsive to steroids and several other drugs,
such as ATG, daclizumab, MMF and tacrolimus. The
majority of these studies did not allow definitive con-
clusions to be drawn because the groups of patients
were small, quite heterogeneous, pre-treated with sev-
eral conventional and experimental immunosuppres-
sants and had a very short follow-up. The dose of inflix-
imab was 10 mg/kg/day in the majority of the studies
and was repeated weekly for a few courses: this sched-
ule was drawn from clinical experience in rheumatol-
ogy, but adequate pharmacokinetic studies are lacking
in the field of HSCT. Other clinically promising but not
conclusive data came from the experimentation of
etanercept, a genetically engineered TNF-α receptor,
which inhibits TNF-α activity by binding the soluble
form of this cytokine. Clinical responses were reported
in a pediatric case of chronic intestinal GVHD,17 in 15
patients with obstructive or restrictive patterns of lung
injury associated with extensive chronic GVHD,19 and in
Figure 2. Comparison of probability of overall survival
between patients responsive and unresponsive to inflix-
imab therapy. 























haematologica 2004; 89(11):November 2004
Infliximab for steroid-refractory GVHD 
1357
20 patients who received 2 mg /kg/day prednisone and
etanercept as first-line treatment of acute GVHD.20
We observed that the strongest predictive factor for
a favorable outcome after infliximab was when the
intestine was the organ involved by GVHD; moreover,
more frequent responses were reported in younger
patients and those in whom the time between HSCT
and infliximab administration was longer. The MD
Anderson experience suggested that infliximab was
most active on low intestinal tract GVHD.6,8,12 This obser-
vation was confirmed in our series; moreover, we found
that patients who had predominant hepatic involve-
ment or concomitant severe hepatic and intestinal
involvement had a significantly lower response rate. It
could be hypothesized that TNF-α is the principal medi-
ator of intestinal GVHD, but that other cytokines, such
as interleukin-6 and interleukin-10, are involved in skin
and liver GVHD and that these are partially independ-
ent from infliximab inhibition of the TNF-α cascade.21-
22 Patients who had greater benefit from infliximab had
received it at a longer interval after HSCT; these
patients included a few who developed GVHD late in the
3-month period after HSCT or after immune manipula-
tion (donor leukocyte infusion or CyA withdrawal) and
a few who had had GVHD conventionally treated in the
first 3-month period and then received infliximab for a
Table 2. Univariate analysis of possible differences in clinical characteristics between patients responsive and unre-
sponsive to infliximab treatment.
Clinical characteristics  Responsive (%) Unresponsive (%) p value
Age at HSCT (years)
Mean±SD 36.8±18.2 46±14.6 0.03
<35 13/19 68 1/13 8 0.04
Sex: male 15/19 79 7/13 54 0.24
Previous diagnosis:
Acute leukemia 8/19 42 6/13 46 0.9
Previous heavy pretreatment 7/19 37 2/13 15 0.35
Time between diagnosis
and HSCT (months)
Mean±SD 21.6±13.6 24.2±21.8 0.60
≤12 9/19 47 4/13 31 0.57
Full conditioning regimen 12/19 63 7/13 54 0.87
Sibling donor 12/19 63 6/13 46 0.55
Source of stem cells:
BM 11/19 58 6/13  46 0.77
Time between HSCT and
GVHD development (days)
Mean±SD 35.8±37.3 27.7±22.4 0.96
≤ 30 13/19 62 9/13 69 0.73
Time between HSCT and 1st
infliximab dose (days)
Mean±SD 89.2±72.3 43.9±24.1 0.009
≤ 60 9/19  47 11/13 85 0.06
Organs involved by GVHD:
Predominant bowel involvement 15/19  74 4/13 31 0.01
Bowel and liver at the same stage 2/19 11 8/13 62 0.005
Infliximab as second-line 6 /19 31 8/13 42 0.56
treatment for GVHD
HSCT: hematopoietic stem cell transplantation; BM: bone marrow GVHD: graft-versus-host disease; SD: standard deviation; ns: not significant.   
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recurrence of GVHD with clinical features of the acute
form (namely diarrhea and erythema) more than 100
days after the HSCT. The correlation between shorter
time after transplantation and worse response might be
explained by the conditioning regimen having damaged
the intestinal mucosa,23 thus releasing large amounts of
endotoxins, which primed GVHD. The shorter interval
between the conditioning and the GVHD could produce
very high levels of TNF-α that might not be effectively
inhibited by anti-TNF-α therapy.
The outcome of responsive and unresponsive patients
was dramatically different. In fact, all 13 unresponsive
patients died of GVHD shortly after infliximab admin-
istration, while only one out the 19 patients who had
some response died of chronic GVHD of the lung. Oth-
er causes of death in responsive patients were infec-
tions, vascular complications, disease recurrence or pro-
gression alone or in association in 5 out 19 patients. The
13 surviving patients were followed up for a median of
15 months after the infliximab treatment and the
majority had no signs of chronic GVHD or only limited
involvement. In our series we observed several infec-
tious episodes: the etiological agents varied greatly
(bacterial, viral, mycotic and unknown) and the infec-
tions were frequently localized to organs such as lungs,
brain, and bowel, as was to be expected in a population
of severely immunosuppressed patients. It should be
emphasized that 2 patients who responded to inflix-
imab died of proven invasive fungal infections. More-
over, there were 5 cases of pneumonia caused by an
undetermined etiologic agent, which could have been
a fungus. In other series, fungal infections were report-
ed in 38 to 54% of patients treated with infliximab for
acute GVHD.5-6,8,10-12 Recently, Jacobsohn et al.11 reported
that all 6 out 11 patients who developed invasive myco-
sis after infliximab treatment had a fatal outcome. In
these small retrospective series of patients treated with
high-dose steroids and combinations of anti-GVHD
drugs, it is difficult to assess how much the infliximab
influenced the inability to control the fungal disease.
However, it has also been reported that patients who
received infliximab for treatment of Crohn’s disease or
rheumatoid arthritis have an unusually high rate of
extrapulmonary and disseminated tuberculosis or histo-
plasmosis, possible due to defective granuloma forma-
tion and absence of anti-TNF-α mediated macrophage
apoptosis.24-25 The only controlled study in transplanted
patients is that by Marty et al.,26 who demonstrated that
patients who received infliximab to control severe
GVHD had a significantly higher risk and a shorter time
to diagnosis of non-Candida invasive fungal infections
than did conventionally treated patients and that these
differences were independent of the cumulative dose of
steroids received.
Our study has several limitations due to its retro-
spective nature: the collection of data from 8 different
centers, where infliximab was prescribed at the discre-
tion of the attending physicians, and the heterogene-
ity of the additional immunosuppressive agents admin-
istered to the patients.
However, infliximab produced clinical responses in
59% of the largest series of patients with steroid-
refractory acute GVHD ever reported in the literature.
The majority of these responses were obtained in
patients with gastrointestinal involvement and many
were durable: only 4 out of 19 responsive patients pro-
gressed to develop extensive (3 cases) or fatal (1
patient) chronic GVHD.  Infective episodes occurred in
72% of the patients and 3 patients who responded to
infliximab died of infections, 2 of them with proven
fungal diseases. The clinical activity of infliximab and
the possibility of an increased risk of infections are wor-
thy of investigation in prospective trials. Given the sus-
picion of an increased risk of fungal infection, pre-emp-
tive systemic antimycotic therapy should be considered
in the study design for patients who develop severe
GVHD and are treated with infliximab.  
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